Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG-2: Local radiotherapy with or without prophylactic pelvic radiotherapy in oligometastatic prostate cancer
ChiCTR2400083776Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400083776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083776.